Edwards Lifesciences (EW) Misleading Growth Projections Case
$EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform.
After the financial results on July 24, 2024, $EW dropped by over 31%.
$EW investors can join this case to be notified about potential recovery.
Case Details:
On July 24, 2024, Edwards Lifesciences reported weaker-than-expected Q2 financial results, especially for its key product, the Transcatheter Aortic Valve Replacement (TAVR) platform.
Previously, Edwards made optimistic predictions, saying there was a large, under-treated population that would boost demand for TAVR. However, the company overestimated the actual demand for these procedures.
Edwards also didn’t disclose that newer heart treatments, including its own TMTT therapies, affected hospital workflows. Hospitals began prioritizing these newer treatments over TAVR, which slowed its growth.
Despite knowing these challenges, Edwards continued to assure investors that TAVR would grow strongly. The company also made three acquisitions during Q2, hinting at underlying issues with TAVR growth.
On July 24, 2024, Edwards reduced its full-year revenue forecast for TAVR, citing slower-than-expected demand and increased competition from newer treatments.
Following this news, $EW dropped over 31%.
Based on these events, $EW investors filed a claim against Edwards Lifesciences, accusing them of the following:
The company misled investors about TAVR’s growth potential.
It overstated confidence in capturing a large, under-treated patient population.
It failed to disclose the impact of competition from newer therapies on TAVR growth.
Investors believe Edwards Lifesciences misled them by overstating TAVR growth prospects and underestimating the competitive challenges.
Frequently Asked Questions
All persons or entities who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards”) common stock during the period from February 6, 2024, through July 24, 2024, inclusive, and were damaged thereby
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.